122 related articles for article (PubMed ID: 9450573)
1. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone.
Yu WD; McElwain MC; Modzelewski RA; Russell DM; Smith DC; Trump DL; Johnson CS
J Natl Cancer Inst; 1998 Jan; 90(2):134-41. PubMed ID: 9450573
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system.
Light BW; Yu WD; McElwain MC; Russell DM; Trump DL; Johnson CS
Cancer Res; 1997 Sep; 57(17):3759-64. PubMed ID: 9288784
[TBL] [Abstract][Full Text] [Related]
3. Calcitriol (1,25-dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosis.
Flynn G; Chung I; Yu WD; Romano M; Modzelewski RA; Johnson CS; Trump DL
Oncology; 2006; 70(6):447-57. PubMed ID: 17237620
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid regulation of the vitamin D receptor.
Hidalgo AA; Trump DL; Johnson CS
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):372-5. PubMed ID: 20398752
[TBL] [Abstract][Full Text] [Related]
5. Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia.
Endo K; Katsumata K; Iguchi H; Kubodera N; Teramoto T; Ikeda K; Fujita T; Ogata E
J Bone Miner Res; 1998 Sep; 13(9):1378-83. PubMed ID: 9738509
[TBL] [Abstract][Full Text] [Related]
6. Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling.
Bernardi RJ; Trump DL; Yu WD; McGuire TF; Hershberger PA; Johnson CS
Clin Cancer Res; 2001 Dec; 7(12):4164-73. PubMed ID: 11751517
[TBL] [Abstract][Full Text] [Related]
7. 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo.
Hershberger PA; Modzelewski RA; Shurin ZR; Rueger RM; Trump DL; Johnson CS
Cancer Res; 1999 Jun; 59(11):2644-9. PubMed ID: 10363987
[TBL] [Abstract][Full Text] [Related]
8. The antitumor efficacy of calcitriol: preclinical studies.
Johnson CS; Muindi JR; Hershberger PA; Trump DL
Anticancer Res; 2006; 26(4A):2543-9. PubMed ID: 16886662
[TBL] [Abstract][Full Text] [Related]
9. A novel immunosuppressive 1alpha,25-dihydroxyvitamin D3 analog with reduced hypercalcemic activity.
Zügel U; Steinmeyer A; Giesen C; Asadullah K
J Invest Dermatol; 2002 Dec; 119(6):1434-42. PubMed ID: 12485451
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells.
Alagbala AA; Johnson CS; Trump DL; Posner GH; Foster BA
Oncology; 2006; 70(6):483-92. PubMed ID: 17237623
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism.
Deb S; Pandey M; Adomat H; Guns ES
Drug Metab Dispos; 2012 May; 40(5):907-18. PubMed ID: 22301272
[TBL] [Abstract][Full Text] [Related]
12. The effects of 1,25-dihydroxyvitamin D3 and dexamethasone on rat osteoblast-like primary cell cultures: receptor occupancy and functional expression patterns for three different bioresponses.
Chen TL; Hauschka PV; Cabrales S; Feldman D
Endocrinology; 1986 Jan; 118(1):250-9. PubMed ID: 3000737
[TBL] [Abstract][Full Text] [Related]
13. CYP24A1 inhibition enhances the antitumor activity of calcitriol.
Muindi JR; Yu WD; Ma Y; Engler KL; Kong RX; Trump DL; Johnson CS
Endocrinology; 2010 Sep; 151(9):4301-12. PubMed ID: 20591973
[TBL] [Abstract][Full Text] [Related]
14. 1,25-Dihydroxyvitamin D3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts.
Tanaka S; Haji M; Takayanagi R; Tanaka S; Sugioka Y; Nawata H
Endocrinology; 1996 May; 137(5):1860-9. PubMed ID: 8612525
[TBL] [Abstract][Full Text] [Related]
15. New 19-nor-(20S)-1alpha,25-dihydroxyvitamin D3 analogs strongly stimulate osteoclast formation both in vivo and in vitro.
Sato M; Nakamichi Y; Nakamura M; Sato N; Ninomiya T; Muto A; Nakamura H; Ozawa H; Iwasaki Y; Kobayashi E; Shimizu M; DeLuca HF; Takahashi N; Udagawa N
Bone; 2007 Feb; 40(2):293-304. PubMed ID: 17070129
[TBL] [Abstract][Full Text] [Related]
16. Additive immunosuppressive effects of 1,25-dihydroxyvitamin D3 and corticosteroids on TH1, but not TH2, responses.
Jirapongsananuruk O; Melamed I; Leung DY
J Allergy Clin Immunol; 2000 Nov; 106(5):981-5. PubMed ID: 11080724
[TBL] [Abstract][Full Text] [Related]
17. Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model.
Ahmed S; Johnson CS; Rueger RM; Trump DL
J Urol; 2002 Aug; 168(2):756-61. PubMed ID: 12131364
[TBL] [Abstract][Full Text] [Related]
18. Combined effects of dexamethasone and 1,25-dihydroxyvitamin D3 on parathyroid hormone secretion in cultured bovine parathyroid cells.
Sugimoto T; Brown AJ; Ritter C; Morrissey J; Slatopolsky E; Martin KJ
Endocrinology; 1989 Aug; 125(2):638-41. PubMed ID: 2546741
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone.
Saunders DE; Christensen C; Williams JR; Wappler NL; Lawrence WD; Malone JM; Malviya VK; Deppe G
Anticancer Drugs; 1995 Aug; 6(4):562-9. PubMed ID: 7579560
[TBL] [Abstract][Full Text] [Related]
20. Dexamethasone increases 1,25-dihydroxyvitamin D3 receptor levels and augments bioresponses in rat osteoblast-like cells.
Chen TL; Hauschka PV; Feldman D
Endocrinology; 1986 Mar; 118(3):1119-26. PubMed ID: 3004896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
